Adaptive Biotechnologies Corp Stock Filter Stocks by Fundamentals
| ADPT Stock | USD 6.39 0.07 1.11% |
Adaptive Biotechnologies Corp fundamentals help investors to digest information that contributes to Adaptive Biotechnologies' financial success or failures. It also enables traders to predict the movement of Adaptive Stock. The fundamental analysis module provides a way to measure Adaptive Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adaptive Biotechnologies stock.
Adaptive | Shares Owned by Institutions |
Adaptive Biotechnologies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adaptive Biotechnologies from analyzing Adaptive Biotechnologies' financial statements. These drivers represent accounts that assess Adaptive Biotechnologies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adaptive Biotechnologies' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.1B | 7.8B | 3.9B | 1.1B | 707.5M | 672.1M | |
| Enterprise Value | 2.0B | 7.7B | 3.9B | 1.1B | 871.8M | 828.3M |
Adaptive Biotechnologies ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Adaptive Biotechnologies' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Adaptive Biotechnologies' managers, analysts, and investors.Environmental | Governance | Social |
Adaptive Biotechnologies Institutional Holders
Institutional Holdings refers to the ownership stake in Adaptive Biotechnologies that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Adaptive Biotechnologies' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Adaptive Biotechnologies' value.| Shares | State Street Corp | 2024-09-30 | 2.6 M | Blue Water Life Science Advisors, Llc | 2024-09-30 | 2.1 M | Goldman Sachs Group Inc | 2024-09-30 | 1.7 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.4 M | Pictet Asset Manangement Sa | 2024-09-30 | 1.3 M | Pier Capital, Llc | 2024-09-30 | 1.3 M | Soleus Capital Management, L.p. | 2024-09-30 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1 M | Abrdn Plc | 2024-09-30 | 1 M | Viking Global Investors Lp | 2024-09-30 | 30 M | Rubric Capital Management Lp | 2024-09-30 | 14.4 M |
Adaptive Fundamentals
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (0.70) % | ||||
| Current Valuation | 791.53 M | ||||
| Shares Outstanding | 147.58 M | ||||
| Shares Owned By Insiders | 1.92 % | ||||
| Shares Owned By Institutions | 93.92 % | ||||
| Number Of Shares Shorted | 9.03 M | ||||
| Price To Earning | 0.25 X | ||||
| Price To Book | 4.21 X | ||||
| Price To Sales | 5.32 X | ||||
| Revenue | 170.28 M | ||||
| Gross Profit | (13.66 M) | ||||
| EBITDA | (189.27 M) | ||||
| Net Income | (225.25 M) | ||||
| Cash And Equivalents | 383.74 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 229.43 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 3.93 X | ||||
| Book Value Per Share | 1.52 X | ||||
| Cash Flow From Operations | (156.32 M) | ||||
| Short Ratio | 6.68 X | ||||
| Earnings Per Share | (1.34) X | ||||
| Target Price | 7.58 | ||||
| Number Of Employees | 709 | ||||
| Beta | 1.45 | ||||
| Market Capitalization | 943.03 M | ||||
| Total Asset | 661.13 M | ||||
| Retained Earnings | (1.14 B) | ||||
| Working Capital | 322.17 M | ||||
| Current Asset | 118.69 M | ||||
| Current Liabilities | 59.26 M | ||||
| Net Asset | 661.13 M |
About Adaptive Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adaptive Biotechnologies Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptive Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptive Biotechnologies Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.